Aptinyx Inc. is a biopharmaceutical company focused on discovery and development of transformative therapies for challenging neurological disorders. Aptinyx has a proven platform for discovering compounds that enhance synaptic plasticity, or strengthen the network for neural cell communication. Molecules discovered by Aptinyx achieve this through a novel mechanism that modulates NMDA receptors, resulting in drugs that are both highly effective and well tolerated.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/10/16 | $65,000,000 | Series A |
Adams Street Partners Beecken Petty O'Keefe & Company Frazier Healthcare Goudy Park Capital Longitude Capital LVP Life Sciences Ventures New Leaf Venture Partners Northwestern University Osage University Partners PathoCapital | undisclosed |
| 12/18/17 | $70,000,000 | Series B |
Adage Capital Management Adams Street Partners Agent Capital Bain Capital  Frazier Healthcare HBM Healthcare Investments Longitude Capital LVP Life Sciences Ventures Nan Fung New Leaf Venture Partners Partner Fund Management Rock Springs Capital | undisclosed |
